Joseph F Arboleda-Velasquez
Overview
Explore the profile of Joseph F Arboleda-Velasquez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun G, Wang C, Mazzarino R, Perez-Corredor P, Davtyan H, Blurton-Jones M, et al.
Cell Rep
. 2024 Nov;
43(12):114982.
PMID: 39612244
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder characterized by extracellular amyloid plaques and neuronal Tau tangles. A recent study found that the APOE3 Christchurch (APOECh) variant could delay...
2.
OHare M, Miller W, Arevalo-Alquichire S, Amarnani D, Apryani E, Perez-Corredor P, et al.
Sci Transl Med
. 2024 Nov;
16(775):eadh0994.
PMID: 39602510
Messenger RNA (mRNA)-based therapies are a promising approach to medical treatment. Except for infectious diseases, no other disease has mRNA-based therapies available. The eye is an ideal model for mRNA...
3.
Lopera F, Arboleda-Velasquez J
N Engl J Med
. 2024 Oct;
391(17):1661.
PMID: 39476353
No abstract available.
4.
Readhead B, Klang E, Gisladottir U, Vandromme M, Li L, Quiroz Y, et al.
Mol Psychiatry
. 2024 Oct;
PMID: 39379683
Recent studies suggest that heparan sulfate proteoglycans (HSPG) contribute to the predisposition to, protection from, and potential treatment and prevention of Alzheimer's disease (AD). Here, we used electronic health records...
5.
Langella S, Bonta K, Chen Y, Su Y, Vasquez D, Aguillon D, et al.
Alzheimers Res Ther
. 2024 Oct;
16(1):208.
PMID: 39354618
Background: Apolipoprotein E (APOE) genotypes have been suggested to influence cognitive impairment and clinical onset in presenilin-1 (PSEN1) E280A carriers for autosomal dominant Alzheimer's disease (ADAD). Less is known about...
6.
Quiroz Y, Aguillon D, Aguirre-Acevedo D, Vasquez D, Zuluaga Y, Baena A, et al.
N Engl J Med
. 2024 Jun;
390(23):2156-2164.
PMID: 38899694
Background: Variants in and (encoding apolipoprotein E and presenilin 1, respectively) alter the risk of Alzheimer's disease. We previously reported a delay of cognitive impairment in a person with autosomal...
7.
Perez-Corredor P, Vanderleest T, Vacano G, Sanchez J, Villalba-Moreno N, Marino C, et al.
Front Mol Neurosci
. 2024 Apr;
17:1373568.
PMID: 38571814
A patient with the E280A mutation and homozygous for Christchurch () displayed extreme resistance to Alzheimer's disease (AD) cognitive decline and tauopathy, despite having a high amyloid burden. To further...
8.
Nelson M, Liu P, Agrawal A, Yip O, Blumenfeld J, Traglia M, et al.
Nat Neurosci
. 2023 Nov;
26(12):2104-2121.
PMID: 37957317
Apolipoprotein E4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer's disease (LOAD), leading to earlier age of clinical onset and exacerbating pathologies. There is a critical need to...
9.
Marino C, Perez-Corredor P, OHare M, Heuer A, Chmielewska N, Gordon H, et al.
Alzheimers Dement
. 2023 Oct;
20(2):819-836.
PMID: 37791598
Introduction: We discovered that the APOE3 Christchurch (APOE3Ch) variant may provide resistance to Alzheimer's disease (AD). This resistance may be due to reduced pathological interactions between ApoE3Ch and heparan sulfate...
10.
Langella S, Barksdale N, Vasquez D, Aguillon D, Chen Y, Su Y, et al.
Nat Commun
. 2023 Aug;
14(1):5120.
PMID: 37612284
Autosomal dominant Alzheimer's disease (ADAD) is genetically determined, but variability in age of symptom onset suggests additional factors may influence cognitive trajectories. Although apolipoprotein E (APOE) genotype and educational attainment...